カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のアダリムマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Adalimumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23SM7763）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23SM7763
■ 発行日：2023年9月
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：108
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のアダリムマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界のアダリムマブモノクローナル抗体バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のアダリムマブモノクローナル抗体バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- アダリムマブモノクローナル抗体バイオシミラーの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

アダリムマブモノクローナル抗体バイオシミラー市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・シリンジ、ペン

用途別セグメント
・強直性脊椎炎、関節リウマチ、クローン病、その他

主要な市場プレーヤー
・Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、アダリムマブモノクローナル抗体バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なアダリムマブモノクローナル抗体バイオシミラーメーカーの企業概要、2019年～2022年までのアダリムマブモノクローナル抗体バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なアダリムマブモノクローナル抗体バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別アダリムマブモノクローナル抗体バイオシミラーの販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのアダリムマブモノクローナル抗体バイオシミラーのタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのアダリムマブモノクローナル抗体バイオシミラー市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびアダリムマブモノクローナル抗体バイオシミラーの産業チェーンを掲載しています。
・第14、15章では、アダリムマブモノクローナル抗体バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– アダリムマブモノクローナル抗体バイオシミラーの概要
– タイプ別分析（2018年vs2022年vs2029年）：シリンジ、ペン
– 用途別分析（2018年vs2022年vs2029年）：強直性脊椎炎、関節リウマチ、クローン病、その他
– 世界のアダリムマブモノクローナル抗体バイオシミラー市場規模・予測
– 世界のアダリムマブモノクローナル抗体バイオシミラー生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：シリンジ、ペン
・用途別分析2018年-2029年：強直性脊椎炎、関節リウマチ、クローン病、その他
・アダリムマブモノクローナル抗体バイオシミラーの北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・アダリムマブモノクローナル抗体バイオシミラーのヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・アダリムマブモノクローナル抗体バイオシミラーのアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・アダリムマブモノクローナル抗体バイオシミラーの南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・アダリムマブモノクローナル抗体バイオシミラーの中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Adalimumab Monoclonal Antibody Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab Monoclonal Antibody Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Cadila Healthcare
2.1.1 Cadila Healthcare Details
2.1.2 Cadila Healthcare Major Business
2.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Cadila Healthcare Recent Developments/Updates
2.2 Torrent Pharmaceuticals
2.2.1 Torrent Pharmaceuticals Details
2.2.2 Torrent Pharmaceuticals Major Business
2.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Torrent Pharmaceuticals Recent Developments/Updates
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Amgen Recent Developments/Updates
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Boehringer Ingelheim Recent Developments/Updates
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Novartis Recent Developments/Updates
2.6 Samsung Bioepis
2.6.1 Samsung Bioepis Details
2.6.2 Samsung Bioepis Major Business
2.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Samsung Bioepis Recent Developments/Updates
2.7 Viatris
2.7.1 Viatris Details
2.7.2 Viatris Major Business
2.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.7.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Viatris Recent Developments/Updates
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pfizer Recent Developments/Updates
2.9 Fresenius Kabi
2.9.1 Fresenius Kabi Details
2.9.2 Fresenius Kabi Major Business
2.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Fresenius Kabi Recent Developments/Updates
2.10 Coherus
2.10.1 Coherus Details
2.10.2 Coherus Major Business
2.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Coherus Recent Developments/Updates
3 Competitive Environment: Adalimumab Monoclonal Antibody Biosimilar by Manufacturer
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab Monoclonal Antibody Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab Monoclonal Antibody Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab Monoclonal Antibody Biosimilar Market: Region Footprint
3.5.2 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
7.3.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
8.3.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
10.3.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
12.2 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
12.3 Adalimumab Monoclonal Antibody Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Adalimumab Monoclonal Antibody Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab Monoclonal Antibody Biosimilar
13.3 Adalimumab Monoclonal Antibody Biosimilar Production Process
13.4 Adalimumab Monoclonal Antibody Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab Monoclonal Antibody Biosimilar Typical Distributors
14.3 Adalimumab Monoclonal Antibody Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Cadila Healthcare Major Business
Table 5. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 6. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Cadila Healthcare Recent Developments/Updates
Table 8. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Torrent Pharmaceuticals Major Business
Table 10. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 11. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Torrent Pharmaceuticals Recent Developments/Updates
Table 13. Amgen Basic Information, Manufacturing Base and Competitors
Table 14. Amgen Major Business
Table 15. Amgen Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 16. Amgen Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Amgen Recent Developments/Updates
Table 18. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 21. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Boehringer Ingelheim Recent Developments/Updates
Table 23. Novartis Basic Information, Manufacturing Base and Competitors
Table 24. Novartis Major Business
Table 25. Novartis Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 26. Novartis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Novartis Recent Developments/Updates
Table 28. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 29. Samsung Bioepis Major Business
Table 30. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 31. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Samsung Bioepis Recent Developments/Updates
Table 33. Viatris Basic Information, Manufacturing Base and Competitors
Table 34. Viatris Major Business
Table 35. Viatris Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 36. Viatris Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Viatris Recent Developments/Updates
Table 38. Pfizer Basic Information, Manufacturing Base and Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 41. Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Pfizer Recent Developments/Updates
Table 43. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 44. Fresenius Kabi Major Business
Table 45. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 46. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Fresenius Kabi Recent Developments/Updates
Table 48. Coherus Basic Information, Manufacturing Base and Competitors
Table 49. Coherus Major Business
Table 50. Coherus Adalimumab Monoclonal Antibody Biosimilar Product and Services
Table 51. Coherus Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Coherus Recent Developments/Updates
Table 53. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Adalimumab Monoclonal Antibody Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Adalimumab Monoclonal Antibody Biosimilar Production Site of Key Manufacturer
Table 58. Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
Table 59. Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
Table 60. Adalimumab Monoclonal Antibody Biosimilar New Market Entrants and Barriers to Market Entry
Table 61. Adalimumab Monoclonal Antibody Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Adalimumab Monoclonal Antibody Biosimilar Raw Material
Table 121. Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar Raw Materials
Table 122. Adalimumab Monoclonal Antibody Biosimilar Typical Distributors
Table 123. Adalimumab Monoclonal Antibody Biosimilar Typical Customers
List of Figures
Figure 1. Adalimumab Monoclonal Antibody Biosimilar Picture
Figure 2. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Syringe Examples
Figure 5. Pen Examples
Figure 6. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Ankylosing Spondylitis Examples
Figure 9. Rheumatoid Arthritis Examples
Figure 10. Crohn’s Disease Examples
Figure 11. Other Examples
Figure 12. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Adalimumab Monoclonal Antibody Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Adalimumab Monoclonal Antibody Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Adalimumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Adalimumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 54. China Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Adalimumab Monoclonal Antibody Biosimilar Market Drivers
Figure 75. Adalimumab Monoclonal Antibody Biosimilar Market Restraints
Figure 76. Adalimumab Monoclonal Antibody Biosimilar Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Adalimumab Monoclonal Antibody Biosimilar in 2022
Figure 79. Manufacturing Process Analysis of Adalimumab Monoclonal Antibody Biosimilar
Figure 80. Adalimumab Monoclonal Antibody Biosimilar Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のベバシズマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のレミケード（インフリキシマブ）モノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析
  • 世界のリツキサン（リツキシマブ）モノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析
  • 世界のチロゲン&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のアバスチンバイオシミラー市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23SM7763 )"世界のアダリムマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Adalimumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。